🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "major milestone" in the effort against increasingly resistant strains of the bacteria, according to scientists.

A Global Public Health Issue

The sexually transmitted infection are escalating around the world, with estimates suggesting over 82 million instances per year. Especially elevated rates are observed in the African continent and countries within the WHO's designated area, which includes Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune step in the context of growing infection rates, escalating drug resistance and the very limited available drugs currently available.”

Public health authorities are particularly alarmed about the surge in antibiotic-resistant strains. The global health body has listed it as a "critical concern". Recent surveillance found that the effectiveness of key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Treatment Options Receive Clearance

One new antibiotic, marketed under the name Nuzolvence, was approved by the US FDA in December for combating gonorrhoea. This infection can lead to major issues, including infertility. Researchers believe that focused deployment of this new drug will help hinder the development of resistance.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This drug, which is employed against UTIs, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for medication research. The non-profit organisation GARDP collaborated with the drug firm its industry partner to bring it to fruition.

“This authorization represents a significant shift in the management of superbug gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Clinical Trial Results and Global Access

According to findings detailed in a prominent scientific publication, zoliflodacin cured the vast majority of genital gonorrhoea infections. This puts it on an equal footing with the current standard treatment, which involves two antibiotics. The study enrolled over 900 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the ability to make available and distribute the drug in numerous regions with limited resources.

Doctors directly involved have voiced positive views. Access to a easy-to-administer therapy of this kind is described as a "critical tool" for gonorrhoea control. This is deemed vital to alleviate the strain of the disease for patients and to stop the proliferation of highly drug-resistant gonorrhoea around the world.